Memorial Sloan Kettering Cancer Center*

Clinical research site in New York, New York · 1275 YORK AVE, M1443, NEW YORK, NY 10065-6007 · (212) 639-6946 · Website

Part of Memorial Sloan Kettering

As of July 2026, 506 paid clinical trials are recruiting at Memorial Sloan Kettering Cancer Center* in New York, New York. Active studies at this site cover conditions such as Breast Cancer, Prostate Cancer and Endometrial Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Memorial Sloan Kettering Cancer Center* (506)

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma

61 locations incl. Los Angeles

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07392892·Phase 2, Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

for Non-small Cell Lung Cancer (NSCLC)

37 locations incl. Daphne

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07361497·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

for CRC (Colorectal Cancer)

67 locations incl. Tucson

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT07284849·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

for Breast Neoplasms

28 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: Female·Age: 18+

Code: NCT07287098·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

29 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07266441·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

for Pancreatic Cancer

29 locations incl. Los Angeles

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07252232·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

28 locations incl. Little Rock

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07258511·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

34 locations incl. Phoenix

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07221149·Phase 2, Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

for Carcinoma, Transitional Cell

62 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07218380·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for Ovarian Neoplasms

88 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07213804·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

116 locations incl. Anchorage

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

for Non-small Cell Lung Cancer

28 locations incl. Fresno

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT07195695·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

for HER2-positive Breast Cancer

22 locations incl. Long Beach

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07102381·Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

86 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

81 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

for Urothelial Cancer

33 locations incl. Gilbert

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07106762·Phase 2, Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

52 locations incl. Gilbert

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

88 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

for Lumbar Spinal Stenosis

2343 locations incl. Athens

Sponsor: Stryker Instruments

Sex: All·Age: 18+

Code: NCT03072927·Recruiting·Listed Mar 2017

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

77 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for NSCLC (Non-small Cell Lung Cancer)

43 locations incl. Birmingham

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06881784·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

for Breast Cancer

54 locations incl. Phoenix

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06790693·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

for Solid Tumors

43 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT03486873·Phase 3·Recruiting·Listed Apr 2018

Apply to this trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

26 locations incl. Cerritos

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

for Advanced Solid Tumor

24 locations incl. Tucson

Sponsor: Synthekine

Sex: All·Age: 18+

Code: NCT05098132·Phase 1, Phase 2·Recruiting·Listed Oct 2021

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

58 locations incl. Anchorage

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for Carcinoma, Non-Small-Cell Lung

48 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

for Multiple Myeloma

28 locations incl. Phoenix

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05201781·Phase 4·Recruiting·Listed Jan 2022

Apply to this trial

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

for Breast Neoplasms

38 locations incl. Hot Springs

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06926868·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

66 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05552222·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

for Glioma

42 locations incl. Birmingham

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT05303519·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

A Study of ASP3082 in Adults With Advanced Solid Tumors

for Solid Tumor

24 locations incl. Duarte

Sponsor: Astellas Pharma Inc

Sex: All·Age: 18+

Code: NCT05382559·Phase 1·Recruiting·Listed May 2022

Apply to this trial

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

for Advanced Breast Cancer

37 locations incl. Springdale

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06638307·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

48 locations incl. Birmingham

Sponsor: Celgene

Sex: Male·Age: 18+

Code: NCT06764485·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

for Melanoma

31 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05355701·Phase 1·Recruiting·Listed May 2022

Apply to this trial

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

for Breast Cancer

24 locations incl. Los Angeles

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05768139·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

for Triple Negative Breast Cancer

26 locations incl. Phoenix

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05377996·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

for Endometrial Adenocarcinoma

42 locations incl. Phoenix

Sponsor: Acrivon Therapeutics

Sex: Female·Age: 18+

Code: NCT05548296·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

31 locations incl. La Jolla

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2·Recruiting·Listed Oct 2020

Apply to this trial

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

for Metastatic Non Small Cell Lung Cancer

21 locations incl. Gilbert

Sponsor: Iovance Biotherapeutics, Inc.

Sex: All·Age: 18 - 70

Code: NCT04614103·Phase 2·Recruiting·Listed Nov 2020

Apply to this trial

Showing the 40 most relevant of 506 recruiting trials at this site. Browse all with filters →

More research sites in New York

Memorial Sloan Kettering Cancer Center (460 trials)
NYU Langone Health (304 trials)
Icahn School of Medicine at Mount Sinai (257 trials)
Columbia University Irving Medical Center (178 trials)
Memorial Sloan Kettering Cancer Center (All Protocol Activities) (157 trials)
Weill Cornell Medicine (134 trials)
Mount Sinai Hospital (121 trials)
Columbia University Medical Center (119 trials)
Columbia University (105 trials)
Hospital for Special Surgery (66 trials)

Explore more

Paid clinical trials in New York, NY · New York clinical trials